

direction, within the region of amino acids 32-78, and wherein said polypeptide is unglycosylated.

REMARKS

Claims 316 to 359 were entered and are pending in this application.

In the Communication, the Examiner states the claims would be allowable if Applicants corrected an alleged deficiency under 35 U.S.C. §112, second paragraph, by adding a "second component, such as a carrier" to the independent claims. Support for such amendment can be found in the specification at page 29, line 20 to page 30, line 2, where standard methods of producing pharmaceuticals are discussed, and in original claim 19, which explicitly recites a carrier.


CONCLUSION

Applicants urge that entry of this amendment is proper as it responds to the Examiner's suggestion and puts this case in condition for allowance. Examiner Saoud is invited to contact the undersigned attorney for applicants for any reason in furtherance of the allowance of the above claims.

Respectfully submitted,

Date: January 14, 2003

Heller Ehrman White & McAuliffe LLP
1666 K Street, N.W., Suite 300
Washington, D.C. 20006-4004
Telephone: (202) 912-2000
Facsimile: (202) 912-2020


Patricia D. Granados
Attorney for Applicant
Reg. No.: 33,683

Customer No. 26633



26633

PATENT TRADEMARK OFFICE

VERSION WITH MARKINGS TO SHOW CHANGES MADE

316. (Amended) A pharmaceutical composition comprising **a carrier and** an isolated keratinocyte growth factor (KGF) polypeptide prepared by expressing in a host cell a DNA encoding a polypeptide having a sequence comprising amino acids 32 - 194 of Figure 7.

321. (Amended) A pharmaceutical composition comprising **a carrier and** an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32 to 194 of Figure 7 or comprises a segment of said polypeptide, wherein said polypeptide and segment thereof has mitogenic activity on BALB/MK cells.

329. (Amended) A pharmaceutical composition comprising **a carrier and** an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises the amino acids 32-194 of Figure 7 or comprises a segment of said polypeptide which is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

333. (Amended) A pharmaceutical composition comprising **a carrier and** an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32-194 of Figure 7 or comprises a segment of said polypeptide which is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.

335. (Amended) The pharmaceutical composition of claim 333, wherein said polypeptide or segment thereof has mitogenic activity on BALB/MK [.]keratinocyte cells

337. (Amended) A pharmaceutical composition comprising **a carrier and** an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32-194 of Figure 7 or comprises a segment of said polypeptide which is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is

truncated from an N terminus to C terminus direction, within the region of amino acids 32-78 and is truncated from the C terminus toward the N terminus, within the region of amino acids 194 to 189.

341. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32-194 of Figure 7.

343. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide prepared by expressing in a host cell a DNA encoding an amino acid sequence comprising amino acids 32-194 of Figure 7 or encoding an amino acid sequence which is a segment of amino acids 32-194 of Figure 7, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78.

347. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide, wherein said polypeptide comprises amino acids 32 to 194 of Figure 7 or comprises a segment of said polypeptide, and wherein said polypeptide and segment thereof has mitogenic activity on epithelial cells.

353. (Amended) The pharmaceutical composition of claim 347, wherein an amount of said polypeptide or segment thereof, that stimulates maximal thymidine incorporation in BALB/MK[.] keratinocyte cells, stimulates less than 1/50'th of the maximal thymidine incorporation in NIH/3T3 cells stimulated by aFGF or bFGF.

354. (Amended) The pharmaceutical composition of claim 347, wherein an amount of said polypeptide or segment thereof that stimulates maximal[.] thymidine incorporation in BALB/MK keratinocyte cells, stimulates less than 1/10th of the maximal thymidine incorporation in[,] NIH/3T3 fibroblasts stimulated by EGF or TGF-alpha.

356. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide comprising a segment of amino acids 32-94 of Figure 7, wherein said polypeptide and segment thereof has mitogenic activity on epithelial cells and wherein said polypeptide is unglycosylated.

357. (Amended) A pharmaceutical composition comprising a carrier and an isolated keratinocyte growth factor (KGF) polypeptide comprising a segment of amino acids 32-194 of Figure 7, wherein the segment is that part of the amino acid sequence of Figure 7 that remains after the amino acid sequence of Figure 7 is truncated from an N terminus to C terminus direction, within the region of amino acids 32-78, and wherein said polypeptide is unglycosylated.